Related Experiment Video

Updated: Jun 30, 2026

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

mTORC1 inhibitors: is temsirolimus in renal cancer telling us how they really work?

C Le Tourneau1, S Faivre, M Serova

  • 1Department of Medical Oncology, APHP and INSERM U728, RayLab, Beaujon University Hospital, Clichy, France.

British Journal of Cancer
|September 18, 2008
PubMed

Insights

Targeting the mTOR pathway with drugs like temsirolimus shows promise for improving survival in advanced renal cell carcinoma patients. This review explores the mechanisms of action for rapalogues in treating this cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • The PI3K/AKT/mTOR signaling pathway regulates critical cellular functions in cancer and endothelial cells.
  • mTOR's role in cancer cell proliferation, survival, and tumor angiogenesis is increasingly understood.
  • Rapamycin derivatives (rapalogues) inhibit mTOR/Raptor complex 1, showing antiproliferative effects in various cancers.

Purpose of the Study:

  • To review the mechanisms of action of rapalogues.
  • To focus on the antitumour effects of rapalogues in renal cell carcinoma (RCC) patients.

Main Methods:

  • Literature review of studies on mTOR inhibitors and renal cell carcinoma.
  • Analysis of preclinical and clinical data on rapalogue efficacy.
  • Exploration of the molecular pathways targeted by rapalogues in RCC.

Main Results:

  • Temsirolimus, an mTOR inhibitor, demonstrated improved survival in a Phase III trial for advanced RCC.
  • Rapalogues exhibit complex antitumour effects in RCC, including cell cycle arrest and apoptosis.
  • Inhibition of tumor angiogenesis via the HIF1alpha-VEGF/VEGFR pathway is another key mechanism.

Conclusions:

  • Targeting the mTOR pathway is a validated strategy for advanced RCC.
  • Rapalogues offer a promising therapeutic approach through direct antiproliferative and anti-angiogenic effects.
  • Further research is needed to elucidate the predominant mechanisms of rapalogues in RCC patients.

More Related Videos

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a rapamycin-insensitive companion...